Recent news on Depodur

FDA Grants Full Approval for DepoCyt for the Treatment of ...  -  Apr 20, 2007
PharmaLive.com (press release),Revenues are generated from two marketed products: DepoCyt for lymphomatous meningitis and DepoDur for the treatment of post-surgical pain.

Paul Capital Healthcare Amends Agreements with SkyePharma PLC  -  27 Mar 2007
PharmaLive.com (press release),...with additional contingent payments linked to the future sales performance of DepoDur, a pain management product of SkyePharma's injectables business

Charges Cause Profit Drop At Endo  -  Feb 23, 2007
Chester Daily Local Online,...charges related to the company’s decision to terminate a co-development and commercialization agreement with SkyePharma for the pain medicine DepoDur,

Del. Department of Labor Employer Conference slated for May 16  -  Feb 23, 2007
The News Journal,One-time charges, including $31.3 million related to the company's decision to drop promotion of its DepoDur product, caused fourth-quarter net earnings to

Endo 4Q earnings drop 80%  -  Feb 22, 2007
San Antonio Business Journal,...with SkyePharma for the pain medicine DepoDur and a $26 million charge for a write-off connected to Endo's October 2006 acquisition of RxKinetix Inc.,

Endo Pharmaceuticals Reports Fourth Quarter and Full-Year 2006 ...  -  Feb 22, 2007
PharmaLive.com (press release),...discontinue promotion of DepoDur(R) and an impairment of the Synera(TM) intangible asset resulting from the redeployment of Endo's hospital sales force,

SkyePharma aims for $82m with sale of injectable business  -  Jan 4, 2007
In-PharmaTechnologist.com,The injectables business is based in San Diego in the US and its products include DepoCyt (cytarabine)for lymphomatous meningitis and DepoDur (morphine

SkyePharma injectables business sale may net $82 million  -  Jan 9, 2007
Pharma Times (subscription),The injectables business, which includes two marketed products, DepoCyt (cytarabine) for lymphomatous meningitis and the painkiller DepoDur (morphine),

SkyePharma agrees to sell SD unit  -  Jan 17, 2007
San Diego Union Tribune,The San Diego unit's main products are DepoCyt, a cancer treatment, and DepoDur for post-operative pain. SkyePharma chief executive Frank Condella said the

SkyePharma to Sell Injectable Business  -  Jan 3, 2007
Houston Chronicle,...with up to an additional $12.5 million payable if worldwide sales of DepoDur, a product of the injectable business, reach certain thresholds.

RPT SkyePharma to sell injectable ops to Blue Acquisition - UPDATE  -  Jan 11, 2007
Hemscott,...with an additional 12.5 mln usd available if sales of injectable product DepoDur reach certain thresholds. simon.meads@thomson.com rda/hjp/sjm/am/sjm/ks.

SkyePharma to sell injectable ops to Blue Acquisition - UPDATE  -  Jan 9, 2007
Hemscott,...to a fixed amortisable note of 92.5 mln usd, with an additional 12.5 mln usd available if sales of injectable product DepoDur reach certain thresholds.

Endo releases 2007 earnings guidance  -  Jan 4, 2007
BusinessWeekAlso, the company is ending its collaboration with SkyePharma PLC over DepoDur. It plans on redeploying its hospital sales force to focus on Opana.

SkyePharma PLC announces Injectable Sale & Placing  -  Jan 4, 2007
Genetic Engineering News (press release),Its products include DepoCyt(R), a treatment for a lymphomatous meningitis, and DepoDur(TM) for post operative pain. The ordinary shares in the Placing have

Endo Guides FY07 EPS Below Consensus  -  Jan 8, 2007
Trading Markets,Additionally, Endo said it has notified SkyePharma of its intent to terminate its development and commercialization agreement for DepoDur.

Craig T. Hartrick, MD and Gavin Martin, MD  Nov 1, 2006
...ondansetron was allowed. Furthermore, DepoDur was not dosed according to age but rather by random assignment. Because no significant ... -Journal of Bone and Joint Surgery (subscription) Evaluation of a Single-Dose, Extended-Release Epidural Morphine ...  Nov 1, 2006
...and a 32% rate of hypoxia, with 96% of these mostly elderly patients requiring supplemental oxygen), the authors conclude that "...epidural DepoDur was a safe ... -Journal of Bone and Joint Surgery (subscription) Endo Pharmaceuticals Reports Third Quarter 2006 Financial Results  Oct 24, 2006
DepoDur(R). Net sales of DepoDur(R) were $0.6 million for the three months ended September 30, 2006. The company began promoting ... -Drug Newswire (press release), Endo Pharma Q3 EPS Dips Yet Tops Estimate; Reiterates FY06 ...  Oct 19, 2006
DepoDur's net sales for the third quarter amounted to $0.6 million, while combined sales of all other branded products totaled $2.2 million for the three ... -Trading Markets, Endo Pharmaceuticals Reports 2006 Second Quarter Financial Results  Jul 20, 2006
DepoDur(R). Net sales of DepoDur(R) were $0.7 million for the three months ended June 30, 2006. The company began promoting DepoDur ... -MSN Money

SkyePharma PLC - Annual General Meeting Statement  Jun 28, 2006
...certain recent developments. Our injectable product DepoDur(TM) for post-operative pain was approved in the UK in May. This approval ... -International News Service



‘Running The Business’ Now Again Focus For SkyePharma  Mar 14, 2006
There are two marketed products: DepoCyt, a cancer treatment, and Depodur, a controlled-release formulation of morphine for postoperative pain. ... - BioWorld Online (subscription)

Shareholders land punches but fail to score a knock-out on ...  Mar 10, 2006
DepoDur, the group's pain treatment, last year reported sales of only $5m. Mr Karabelas promised to focus on returning the group to profitability. ... - Financial Times

SkyePharma defeats shareholder revolt  Mar 10, 2006
San Diego-based injectables unit, which has two marketed products - DepoCyt (cytarabine) for lymphomatous meningitis and the painkiller DepoDur (morphine), as ... - Pharma Times (subscription)

Endo Pharmaceuticals Reports Fourth Quarter and Full-Year 2005 ...  Feb 15, 2006
DepoDur(R). Net sales of DepoDur(R) were $0.9 million for the three months ended December 31, 2005 and $3.9 million for the twelve months ended December 31 ... - MSN Money

Business Digest  Feb 25, 2006
A “warts and all� assessment of the firm’s portfolio is also likely to reveal a delay in the commercialisation of DepoDur, a morphine-based painkiller. ... - The Sunday Times,

SkyePharma sinks as board defies rebels  Feb 2, 2006
...strategic review, the company said it is instead opting to sell its injectable drugs division, which comprises cancer drug DepoCyt and Depodur for treating ... - Times Online,

SkyePharma Announces Appointment of New Chairman and Outcome of ...  Feb 2, 2006
The injectables business, primarily located in San Diego, consists of two marketed products, DepoCyt® for a complication of cancer and Depodur® for the ... - Yahoo! News

SkyePharma sinks as board defies rebels  Feb 2, 2006
...strategic review, the company said it is instead opting to sell its injectable drugs division, which comprises cancer drug DepoCyt and Depodur for treating ... - Times Online

SkyePharma defies rebels by appointing Karabelas to chair  Feb 2, 2006
The division, which makes DepoCyt to treat a complication of cancer and Depodur for post-surgery pain, has attracted interest from several bidders and is worth ... - Independent

SkyePharma Announces Appointment of New Chairman and Outcome of ...  Feb 2, 2006
The injectables business, primarily located in San Diego, consists of two marketed products, DepoCyt(R) for a complication of cancer and Depodur(R) for the ... - PR Newswire

Endo leases marketing rights for new drug  Jan 10, 2006
The drug will be promoted through Endo’s existing 70-person hospital sales force, which currently promotes DepoDur, Lankau said. ... - Chester Daily Local Online

Endo Announces License Agreement With ZARS for Synera(TM), an FDA ...  Jan 9, 2006
...setting." He noted that Endo will promote Synera(TM) through its existing 70-person hospital sales force, which currently promotes DepoDur® (morphine sulfate ... - Yahoo! News

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional